Strateos nabs $56M for SmartLab Platform

By The Science Advisory Board staff writers

June 10, 2021 -- Strateos announced it closed on $56 million in financing to continue to drive innovations on its SmartLab Platform.

Strateos develops remote-access laboratories and lab control software for life science research. Its SmartLab Platform integrates data generation and artificial intelligence automation to accelerate pharmaceutical and synthetic biology research and development.

The financing was led by DCVC and Lux Capital with participation from new investors, including Eli Lilly, Ally Bridge Group, Black Diamond Ventures, Mack & Co., and Castor Ventures, Strateos said.

August Bioservices raises $24M to grow U.S. manufacturing
August Bioservices has raised about $24 million in funding to expand its biomanufacturing capabilities in the U.S.
Engine Biosciences raises $43M for combo genetic platform
Engine Biosciences has raised $43 million to advance its drug discovery and development platform, which uses next-generation combinatorial genetics...
Qualio nabs $50M for electronic management software
Qualio has closed $50 million in funding to expand accessibility to its electronic quality management software and services for life sciences customers...
BioTheryX secures $92M to advance protein degradation oncology pipeline
BioTheryX announced it has secured $92 million in series E financing to advance multiple molecular glues, proteolysis-targeting chimeras, and monovalent...
Flare launches with $82M investment
Biotechnology company Flare Therapeutics announced it has launched with series A financing of $82 million.

Copyright © 2021

Bio-IT World Conference and Expo
September 20-22
Boston, Massachusetts United States
BioProcess International
September 20-23
Boston, Massachusetts United States
Cell and Gene Therapy Manufacturing and Commercialization
September 20-23
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter